Oramed Pharmaceuticals Inc (ORMP)

[humpback]

I think it was the company using the opportunity of good news in order to raise money for their upcoming expenses. I think during the 'mixed security shelf' they can dilute no more than 25% of the float (2-3 million shares) for up to 100 mil. If this is true, then they probably raised 70 plus million to fund future operations (they still need to conduct phase IIb and phase III trials which will cost millions). To me, this is good because the float is still under 12 mill, the company have 70 to 100 mil in capital, and a product that could be a multi billion deal.